November 30,
2004
The US Patent Office recently awarded two additional patents to
ProThera, Inc., parent company of Klaire Labs, for the composition
and methods of use for a unique plant and microbial-derived enzyme
composition. The two new patents, awarded in October and November
2004, are a continuation and extension of two previous related patents
awarded to Klaire Labs in 2001 and 2002. This series of patents
recognizes the administration of physiologically effective amounts
of a purified casomorphinase, a purified gluteomorphinase, a dipepitidylpeptidase,
and/or other active enzymes that act by breaking down peptides from
casein and gluten, i.e. casomorphin and gluteomorphin respectively,
that can mimic opiates in the body.
1) United States Patent 6,808,708. Compositions
and methods relating to reduction of symptoms of autism. October
26, 2004.
2) United States Patent 6,821,514. Compositions
and methods relating to reduction of symptoms of autism. November
23, 2004.
3) United States Patent 6,251,391. Compositions
containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase
for reducing opioid-related symptoms. June 26, 2001.
4) United States Patent 6,447,772. Compositions
and methods relating to reduction of symptoms of autism. September
10, 2002.
|
